Median progression free survival in the selpercatinib group was not reached and was 16.8 months in the cabozantinib/vandetanib group. The Food and Drug Administration ...

The approval of Retevmo is for the treatment of adults and children aged 2 years and older with advanced or metastatic medullary thyroid cancer. The Food and Drug Administration (FDA) approved Retevmo ...

RET fusion-positive NSCLC patients benefit from targeted therapies like Retevmo and Gavreto, recommended by NCCN guidelines for first-line treatment. Gavreto demonstrated a 57% overall response rate ...

The FDA approved selpercatinib for treatment of metastatic medullary thyroid cancer in patients 2 years and older with a RET mutation. Selpercatinib previously received accelerated approval for ...

Biomarker discordance after neoadjuvant systemic therapy and associated patterns of recurrence. Clinical update related to the first-in-human trial of SYS6002 (CRB-701), a next-generation nectin-4 ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Early prediction of prognosis in advanced solid tumor patients using tumor growth rates with g score in early phase clinical trials.